Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer.

Mitogen activated protein (MAP) kinases are well known serine threonine kinases that modulate gene expression, mitosis, cell proliferation and programmed cell death or 'apoptosis' in response to various stresses. Extracellular stress regulated kinase (ERK), c-jun NH2 terminal kinase and p38 are major members of the MAP kinases, and there is now a body of evidence of their involvement in genesis or sensitivity to chemotherapy of human prostate cancers. In this review, we focus on the molecular roles of MAP kinases and their pathological correlations, with particular attention to novel downstream signals through phosphorylation of the Fas-associated death domain protein that effectively regulates not only apoptosis but also the cell cycle in prostate neoplastic cells.

[1]  B. Beattie,et al.  Regulation of Erythropoietin-induced STAT Serine Phosphorylation by Distinct Mitogen-activated Protein Kinases* , 2002, The Journal of Biological Chemistry.

[2]  F. Claessens,et al.  The AF1 and AF2 Domains of the Androgen Receptor Interact with Distinct Regions of SRC1 , 1999, Molecular and Cellular Biology.

[3]  A. Bode,et al.  Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. , 2002, Cancer research.

[4]  J. Isaacs,et al.  Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.

[5]  Mitsutoshi Nakamura,et al.  Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. , 2004, Carcinogenesis.

[6]  Z. Hall.  Cancer , 1906, The Hospital.

[7]  R. Meacham,et al.  Mitogen Activated Protein kinase signal transduction pathways in the prostate , 2004, Cell Communication and Signaling.

[8]  B. Dérijard,et al.  Cdc42 and PAK-mediated Signaling Leads to Jun Kinase and p38 Mitogen-activated Protein Kinase Activation (*) , 1995, The Journal of Biological Chemistry.

[9]  J. Roth,et al.  Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells , 1999, Oncogene.

[10]  K. L. Pierce,et al.  Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.

[11]  Chen Dong,et al.  MAP kinases in the immune response. , 2002, Annual review of immunology.

[12]  G. Romano,et al.  Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases. , 2000, Endocrinology.

[13]  G Bartsch,et al.  Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. , 1999, Cancer research.

[14]  M. Landström,et al.  2-Methoxyestradiol-induced Apoptosis in Prostate Cancer Cells Requires Smad7* , 2005, Journal of Biological Chemistry.

[15]  P. de Souza,et al.  Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. , 1997, British Journal of Cancer.

[16]  D. Baltimore,et al.  Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. , 1998, Science.

[17]  M. Peter,et al.  Phosphorylation of FADD/ MORT1 at Serine 194 and Association with a 70-kDa Cell Cycle-Regulated Protein Kinase1 , 2000, The Journal of Immunology.

[18]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[19]  J. Isaacs,et al.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.

[20]  D. Tindall,et al.  The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. , 1997, Endocrinology.

[21]  S. Katiyar,et al.  Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NF kappa B. , 2004, Carcinogenesis.

[22]  Mitsutoshi Nakamura,et al.  Phosphorylation status of Fas‐associated death domain‐containing protein (FADD) is associated with prostate cancer progression , 2005, The Journal of pathology.

[23]  J. Rhim,et al.  C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  S. Kambhampati,et al.  p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion , 2003, Oncogene.

[25]  Y. Ip,et al.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.

[26]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[27]  K. Shimada,et al.  Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. , 2003, Carcinogenesis.

[28]  M. Wilkinson,et al.  SAPKs and transcription factors do the nucleocytoplasmic tango. , 1998, Genes & development.

[29]  S. Chi,et al.  Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways1 , 2004 .

[30]  J. R. Kim,et al.  Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[32]  P. Kaplan,et al.  Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer , 2003, The Prostate.

[33]  D. Troyer,et al.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  S. Grösch,et al.  Activation of c‐Jun‐N‐terminal‐kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[36]  W. Fang,et al.  ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. , 2004, Cancer letters.

[37]  Teruhiko Fujii,et al.  Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival Pathway* , 2003, Journal of Biological Chemistry.

[38]  M. Gorospe,et al.  Inhibition of c-Jun N-Terminal Kinase 2 Expression Suppresses Growth and Induces Apoptosis of Human Tumor Cells in a p53-Dependent Manner , 2000, Molecular and Cellular Biology.

[39]  L. Zon,et al.  Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase , 1995, Nature.

[40]  R. Katoh,et al.  Poorly differentiated desmin-negative and vimentin-positive leiomyosarcoma of the stomach examined by the immunohistochemical and quick-freezing and deep-etching methods , 1998, Virchows Archiv.

[41]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[42]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[43]  Teiji Wada,et al.  Mitogen-activated protein kinases in apoptosis regulation , 2004, Oncogene.

[44]  P. Walsh.  Hedgehog signalling in prostate regeneration, neoplasia and metastasis. , 2005, The Journal of urology.

[45]  Minoru Takagi,et al.  Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways , 1997, Science.

[46]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[47]  L. Zon,et al.  Cdc42Hs, but Not Rac1, Inhibits Serum-stimulated Cell Cycle Progression at G1/S through a Mechanism Requiring p38/RK* , 1997, The Journal of Biological Chemistry.

[48]  E. Messing,et al.  Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. , 2002, Cancer research.

[49]  G. Johnson,et al.  MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42 , 1997, The EMBO journal.

[50]  J. Aguirre-Ghiso,et al.  Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. , 2001, Molecular biology of the cell.

[51]  J. Chant,et al.  Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway , 1996, Current Biology.